Recently, the use of anticholinergics and biological antibodies (anti-IgE/anti-IL5) was approved depending on the severity of this disease; the use of any combination reduces inflammatory biomarkers and improves the symptoms (Global Initiative for Asthma, 2020). Here, IL5 is linked to asthma.